Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Outcomes in kidney transplantation.

Arjang Djamali1, Nalinee Premasathian, John D Pirsch

  • 1Department of Medicine and Surgery, University of Wisconsin Medical School, Madison, WI 53792, USA.

Seminars in Nephrology
|July 3, 2003
PubMed
Summary

New immunosuppressive drugs like MMF and tacrolimus have improved kidney transplant outcomes by reducing acute rejection. Long-term benefits and managing complications are key for transplant recipients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to Comment on "Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study".

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Impact of older donor age in kidney transplants in a biopsy-based observational study.

JCI insight·2026
Same author

Clazakizumab in the treatment of chronic active antibody-mediated kidney transplant rejection: Results from the IMAGINE phase 3, randomized, double-blind, placebo-controlled study.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2026
Same author

Belatacept Conversion in Kidney Transplant Recipients with Congestive Heart Failure: Survival and 30-Day Readmission Outcomes.

Transplantation proceedings·2025
Same author

A cross-sectional study of the role of epithelial cell injury in kidney transplant outcomes.

JCI insight·2025
Same author

Variations in de novo donor-specific antibody development among HLA-DQ mismatches in kidney transplant recipients.

PloS one·2025

Area of Science:

  • Nephrology
  • Immunology
  • Transplantation Medicine

Background:

  • Over 100,000 kidney transplant recipients in the US have functioning grafts.
  • Advances in immunosuppression have improved short-term graft survival and reduced early mortality.
  • Kidney transplantation prolongs patient survival compared to dialysis.

Purpose of the Study:

  • To review randomized trials of immunosuppressive therapy in kidney transplantation.
  • To discuss complications associated with immunosuppressive drugs.
  • To outline current management of comorbidities in kidney transplant recipients.

Main Methods:

  • Analysis of randomized controlled trials (RCTs) for immunosuppressive drugs.
  • Review of registry analyses for long-term outcomes.
  • Examination of risk factors and management strategies for common complications.

Main Results:

  • Mycophenolate mofetil (MMF) combined with cyclosporine (CSA) and prednisone reduced acute rejection by ~50%.
  • Tacrolimus reduced acute rejection but increased posttransplant diabetes mellitus (PTDM); combination with MMF lowered PTDM incidence.
  • Sirolimus reduced acute rejection and may be less nephrotoxic than calcineurin inhibitors.

Conclusions:

  • Newer immunosuppressants have significantly improved short-term kidney transplant outcomes.
  • Long-term benefits of specific immunosuppressive regimens require further investigation through registry analyses.
  • Managing complications like chronic allograft nephropathy, hypertension, and bone disease is crucial for long-term recipient health.

Related Experiment Videos